GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » EV-to-Revenue

Hyundai Bioscience Co (XKRX:048410) EV-to-Revenue : 64.07 (As of Jun. 19, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hyundai Bioscience Co's enterprise value is ₩728,354 Mil. Hyundai Bioscience Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩11,369 Mil. Therefore, Hyundai Bioscience Co's EV-to-Revenue for today is 64.07.

The historical rank and industry rank for Hyundai Bioscience Co's EV-to-Revenue or its related term are showing as below:

XKRX:048410' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.44   Med: 8.11   Max: 182.5
Current: 64.06

During the past 13 years, the highest EV-to-Revenue of Hyundai Bioscience Co was 182.50. The lowest was 1.44. And the median was 8.11.

XKRX:048410's EV-to-Revenue is ranked worse than
79.84% of 1032 companies
in the Biotechnology industry
Industry Median: 7.57 vs XKRX:048410: 64.06

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-19), Hyundai Bioscience Co's stock price is ₩18250.00. Hyundai Bioscience Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₩286.73. Therefore, Hyundai Bioscience Co's PS Ratio for today is 63.65.


Hyundai Bioscience Co EV-to-Revenue Historical Data

The historical data trend for Hyundai Bioscience Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co EV-to-Revenue Chart

Hyundai Bioscience Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.39 85.25 104.90 136.88 108.92

Hyundai Bioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.56 100.06 115.59 108.92 73.70

Competitive Comparison of Hyundai Bioscience Co's EV-to-Revenue

For the Biotechnology subindustry, Hyundai Bioscience Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyundai Bioscience Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's EV-to-Revenue falls into.



Hyundai Bioscience Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hyundai Bioscience Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=728354.077/11368.809
=64.07

Hyundai Bioscience Co's current Enterprise Value is ₩728,354 Mil.
Hyundai Bioscience Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩11,369 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyundai Bioscience Co  (XKRX:048410) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hyundai Bioscience Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=18250.00/286.725
=63.65

Hyundai Bioscience Co's share price for today is ₩18250.00.
Hyundai Bioscience Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩286.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyundai Bioscience Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyundai Bioscience Co (XKRX:048410) Business Description

Traded in Other Exchanges
N/A
Address
150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines